Filing Details

Accession Number:
0001209191-22-060972
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-13 17:05:28
Reporting Period:
2022-12-09
Accepted Time:
2022-12-13 17:05:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818794 Dyne Therapeutics Inc. DYN Pharmaceutical Preparations (2834) 364883909
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1824673 Jonathan Mcneill C/O Dyne Therapeutics, Inc.
1560 Trapelo Road
Waltham MA 02451
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-09 40,000 $0.00 98,222 No 4 A Direct
Common Stock Disposition 2022-12-12 472 $10.87 97,750 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2022-12-09 63,000 $0.00 63,000 $10.72
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
63,000 2032-12-08 No 4 A Direct
Footnotes
  1. Consists of shares of Common Stock issuable under 40,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.
  2. Includes 69,072 unvested RSUs.
  3. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
  4. Includes 67,490 unvested RSUs.
  5. This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.